Примери за използване на Integrase inhibitor на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Integrase inhibitor Raltegravir.
Antiretroviral- integrase inhibitor Raltegravir.
Integrase Inhibitors Raltegravir 400 mg BID.
The active substance in Isentress, raltegravir,is an integrase inhibitor.
HIV-1 integrase inhibitor(e.g. raltegravir);
One of the active substances in Triumeq, dolutegravir,is an integrase inhibitor.
Integrase inhibitors Dolutegravir 50 mg once daily(daclatasvir 60 mg once daily).
Raltegravir is the first drug in a new class, integrase inhibitors.
In the presence of integrase inhibitor resistance, there are insufficient data to recommend a dose for dolutegravir in children.
Patients were either given the Triumeq combination ora different three-drug combination(Atripla) that did not include an integrase inhibitor.
Vitekta was at least as effective as raltegravir(another integrase inhibitor) when taken in combination with other anti-HIV medicines.
Vitekta has been investigated in one main study involving 712 patients with HIV-1 who had not been treated before with an integrase inhibitor.
The dose is one 50-mg tablet twice a day in patients whose virus is known orsuspected to be resistant to integrase inhibitors; in these patients, giving Tivicay with medicines that decrease its effectiveness should be avoided.
Preliminary data indicate that there is potential for at least some degree of cross-resistance to occur between raltegravir and other integrase inhibitors.
The first of these involved 715 patients whose previous treatment had not included an integrase inhibitor and whose infection was therefore not expected to be resistant to this class of medicines.
This regimen is only suitable for the treatment of HIV-1 infection where there is no known orsuspected resistance to the integrase inhibitor class, or to lamivudine.
Cross-resistance between nevirapine and either HIV protease inhibitors, HIV integrase inhibitors or HIV entry inhibitors is unlikely because the enzyme targets involved are different.
SVR rates were> 94% across combination antiretroviral therapy(cART) regimens, including boosted-PI-,NNRTI-, and integrase inhibitor(INSTI)-based therapies.
Dolutegravir, an integrase inhibitor, blocks an enzyme called integrase while rilpivirine, a non-nucleoside reverse-transcriptase inhibitor, blocks the activity of another enzyme called reverse transcriptase.
Dovato is indicated in the absence of documented orsuspected resistance to the integrase inhibitor class and to lamivudine(see section 4.1).
The second study involved 833 patients given either a combination of Tivicay with two NRTIs ora different three-drug combination(Atripla) that did not include an integrase inhibitor.
Since the recommended dose of dolutegravir is 50 mg twice daily for patients withresistance to integrase inhibitors, the use of Triumeq is not recommended for patients with integrase inhibitor resistance.
The adult dose depends on whether the infection is known orsuspected to be resistant to medicines of the class to which Tivicay belongs(integrase inhibitors).
Dolutegravir stops the activity of an enzyme called integrase(and is known as an integrase inhibitor), while lamivudine stops the activity of reverse transcriptase(and is known as a nucleoside reverse transcriptase inhibitor or NRTI).
It is only used in patients where the virus has not developed resistance to a class of HIV medicines called integrase inhibitors, or to tenofovir or emtricitabine.
In analyzing the cost-eff ectiveness of CART containing integrase inhibitors in the treatment of HIV-positive patients, we came to the conclusion that CART containing bictegravir is dominated by therapies containing elvitegravir and dolutegravir with improved therapeutic effi cacy and lower annual costs therapeutic course.
The Committee concluded that the medicine had demonstrated its effectiveness in both untreated and previously treated patients,including those with resistance to integrase inhibitors.
In the first of these, involving 822 patients,Tivicay once daily was compared with raltegravir(another integrase inhibitor), both given in combination with two other HIV medicines of a different class(known as nucleoside reverse transcriptase inhibitors or NRTIs): 88%(361 of 411 patients) given Tivicay and 85%(351 of 411) given raltegravir responded after 48 weeks of treatment.
Genvoya is indicated for the treatment of human immunodeficiency virus-1(HIV-1)infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows.
However, based on the information retrieved in literature and in the product information of integrase inhibitors containing medicinal products, it could be concluded that the following psychiatric disorders: depression, suicidal ideation and suicidal behaviour(particularly in patients with pre-existing history of psychiatric illness)are class-effect of integrase inhibitors and these are listed in the SmPC of other medicinal products containing integrase inhibitors in monotherapy and in fixed-dose combination(FDC).